Stockreport

Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV) [Yahoo! Finance]

Protagonist Therapeutics, Inc.  (PTGX) 
Last protagonist therapeutics, inc. earnings: 3/10 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.protagonist-inc.com
PDF NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hemat [Read more]